Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03489369
Title Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Symphogen A/S
Indications
Therapies
Age Groups:
Covered Countries USA | CAN


No variant requirements are available.